Overview of metabolomic markers used for diagnosing cardiovascular diseases

At present, metabolomics is an intensively developing approach to the specific diagnosis of cardiovascular diseases. Metabolic analysis allows the study of complete metabolomic profiles and their deviations resulting from changes, for example, gene and RNA expression, protein activity, or environmental factors. Analysis of the metabolomic blood profile helps in solving a large number of scientific and clinical problems, one of which is the search for markers of diseases, in particular, cardiovascular diseases (CVD). Aim of the study was to investigate metabolomic markers used for the diagnosis of cardiovascular diseases on the basis of literature data. 

Material and methods. The literature data was analyzed for key words: cardiovascular diseases, metabolomics, metabolic profile, metabolomic markers in da- tabases PubMed, Scopus, Web of Science, CyberLeninka, PatentDB, Science Direct Open Access, eLibrary. 

Results. Analysis of literature data and patent search confirms the high importance of metabolomic markers in the diagnosis of CVD. In the patent literature, BNP/NT-proBNP is most common used as a metabolic marker of CVD (11.27 %). The use of CRP (8.99 %) and troponin (8.49 %) is also common. PICP (0.02 %), sVCAM-1 (0.09 %), stimulating growth factor ST-2 (0.12 %) and thrombomodulin (0.12 %) as metabolic markers of CVD. 

Conclusions. Against the backdrop of analytical methods, metabolomics is the most important diagnostic area. At the same time, it should be noted that by combining the results of the analysis of metabolic studies with others, for example, genomic and proteomic, one can get a complete picture of the pathogenesis of diseases, assess the risk of complications, and also determine the effectiveness of the treatment.

1. Chaulin A.M. Some modern biomarkers of cardiovascular disease. The Scientific Heritag. 2020;(49):61– 63. [In Russian]. doi: 10.18411/lj-09-2020-21

2. Belenkov Ju.N., Privalova E.V., Kozhevnikova M.V., Korobkova E.O., Il’gisonins I.S., Kaplunova V.Ju., Shakar’janc G.A., Appolonova S.A., Kuharenko A.V., Larcova E.V., Mesonzhik N.V. Metabolic profiling of patients with cardiovascular diseases. Kardiologiya = Cardiology. 2018;58(9):59–62. [In Russian]. doi: 10.18087/cardio.2018.9.10172

3. Chaulin A.M. Biomarkers for risk stratification and identification of life-threatening cardiovascular diseases. Original’nyye issledovaniya = Original Research. 2020;10(9):88–95. [In Russian].

4. Libis R.A., Isaeva E.N., Vdovenko L.G., Basyrova I.R. Brain sodium uretic propeptide as a marker of heart damage in persons with metabolic syndrome. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2015;(4):84–88. [In Russian]. doi: 10.15829/1560-4071-2015-4-84-88

5. Pashhenko E.V., Chesnikova A.I., Kudinov V.I., Terent’ev V.P., Kolomackaja O.E. Calculation of the threshold level and assessment of the dynamics of natriuretic peptide to optimize the management of comorbid patients with thyrotoxicosis and heart failure. Meditsinskiy vestnik Yuga Rossii = Medical Herald of the South of Russia. 2018;9(4):73–80. [In Russian]. doi: 10.21886/2219-8075-2018-9-4-73-80

6. Cao Z., Jia Y., Zhu B. BNP and NT-proBNP as diagnostic biomarkers for cardiac dysfunction in both clinical and forensic medicine. Int. J. Mol. Sci. 2019;20(8):1820. doi: 10.3390/ijms20081820

7. Podzolkov V.I., Tarzimanova A.I., Mohammadi L. Predictors of atrial fibrillation progression in patients with chronic heart failure. Klinicheskaya meditsina = Clinical Medicine. 2017;95(7):613–617. [In Russian]. doi: 10.18821/0023-2149-2017-95-7-613-617

8. Kozlov I.A., Burzhunova M.G., Chumakov M.V., Timerbaev V.H. Perioperative dynamics and clinical significance of the content of B-type natriuretic peptide in the blood of cardiac surgery patients. Obshchaya reanimatologiya = General Reanimatology. 2012;8(4):133. [In Russian]. doi: 10.15360/1813-97792012-4-133

9. Zile M.R., Claggett B.L., Prescott M.F., McMurray J.J.V., Packer Mi., Rouleau J.L., Swedberg K., Desai A.S., Gong J., Shi V.C., Solomon S.D. Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure. J. Am. Coll. Cardiol. 2016;68(22):735–1097. doi: 10.1016/j.jacc.2016.09.931

10. Stelzle D., Shah A.S.V., Anand A., Strachan F.E., Chapman A.R., Denvir M.A., Mills N. L., McAllister D.A. High-sensitivity cardiac troponin I and risk of heart failure in patients with suspected acute coronary syndrome: a cohort study. Eur. Heart J. Qual. Care Clin. Outcomes. 2018;4(1):36–42. doi: 10.1093/ehjqcco/qcx022

11. Ford I., Shah A., Zhang R., McAllister D.A., Strachan F.E., Caslake M., Newby D.E., Packard C.J., Mills N.L. High-sensitivity cardiac troponin, statin therapy, and risk of coronary heart disease. J. Am. Coll. Cardiol. 2016;68:2719–2728. doi: 10.1016/j. jacc.2016.10.020

12. Weinmann K., Werner J., Koenig W., Rottbauer W., Walcher D., Kebler M. Use of cardiac biomarkers for monitoring improvement of left ventricular function by immunoadsorption treatment in dilated cardiomyopathy. Biomolecules. 2019;9(11):654. doi: 10.3390/biom9110654

13. Smáradóttir M.I., Catrinav S.B., Brismar K., Norhammar A., Gyberg V., Mellbin L.G. Copeptin and insulin-like growth factor binding protein-1 during follow-up after an acute myocardial infarction in patients with type 2 diabetes: A report from the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction 2 cohort. Diab. Vasc. Dis. Res. 2019;16(1):22– 27. doi: 10.1177/1479164118804451

14. Morawiec B., Kawecki D. Copeptin: a new marker in cardiology. J. Cardiovasc. Med. (Hagerstown). 2013;14(1):19–25. doi: 10.2459/ JCM.0b013e3283590d59

15. Morawiec B., Kawecki D., Przywara-Chowaniec B., Opara M., Muzyk P., Ho L., Tat L.C., Gabrysiak A., Muller O., Nowalany-Kozielska E. Copeptin as a prognostic marker in acute chest pain and suspected acute coronary syndrome. Dis. Markers. 2018;46:1–8. doi: 10.1155/2018/6597387

16. Sukmanova I.A., Tanana O.S., Ponomarenko I.V., Kosouhov A.P. Copeptin and biomarkers of inflammation in patients with different types of acute coronary syndrome. Kompleksnyye problemy serdechno-sosudistykh zabolevaniy = Complex Issues of Cardiovascular Diseases. 2017;6(4):44–49. [In Russian]. doi: 10.17802/2306-1278-2017-6-4-44-49

17. Maisel A., Mueller C., Neath S.X., Christenson R.H ., Morgenthaler N.G., McCord J., Nowak R.M., Vilke G., Daniels L.B., Hollander J.E., … Peacock W.F. Copeptin helps in the early detection of patients with acute myocardial infarction: primary results of the CHOPIN trial (Copeptin Helps in the early detection Of Patients with acute myocardial INfarction). J. Am. Coll. Cardiol. 2013;62(2):150–160. doi: 10.1016/j. jacc.2013.04.011

18. Meune C., Zuily S., Wahbi K., Claessens Y.-E., Weber S., Chenevier-Gobeaux C. Combination of copeptin and high-sensitivity cardiac troponin T assay in unstable angina and non-ST-segment elevation myocardial infarction: a pilot study. Arch. Cardiovasc. Dis. 2011;104(1):4–10. doi: 10.1016/j. acvd.2010.11.002

19. Nishikimi T., Nakao K., Kangawa K. Adrenomedullin in heart failure: molecular mechanism and therapeutic implication. Current Hypertension Reviews. 2011;7(4):273–283. doi: 10.2174/157340211799304752

20. Abdulaev R.F., Bahshaliev A.B., Kulieva A.D., Huseynzade R.R. Assessment of the dependence of the concentration of endothelin-1 and magnesium in the blood on the severity of coronary heart disease. Kazanskiy meditsinskiy zhurnal = Kazan Medical Journal. 2016;97(4):492–496. [In Russian]. doi: 10.17750/ KMJ2016-492

21. Beljakov V.I., Kuchin S.S., Chernyshov V.N., Аntipov Е.V. Comparative effects of melatonin and agomelatine on blood circulation parameters. Vestnik meditsinskogo instituta «REAVIZ»: reabilitatsiya, vrach i zdorov’ye = Bulletin of the Medical Institute “REAVIZ”: Rehabilitation, Physician and Healt. 2017;6:213–218. [In Russian].

22. Medvedev V.Je., Korovjakova Je.A., Frolova V.I., Gushanskaya E.V. Antidepressant therapy in patients with cardiovascular diseases. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(1):131–140. [In Russian]. doi: 10.14412/2074-2711-2019-1-131-140

23. Mihajlova Z.D., Shalenkova M.A. The role of melatonin in patients with acute coronary syndrome. Kardiologiya: Novosti. Mneniya. Obuchenie = Cardiology: News. Opinions. Education. 2017;2(13):39–44. [In Russian]. doi: 10.24411/2309-1908-2017-00024

24. Kopeckij I.S., Pobozh’eva L.V., Sheveljuk Ju.V. Interrelation of inflammatory periodontal diseases and general somatic diseases. Lechebnoye delo = Medical Care. 2019;2:7–12. [In Russian]. doi: 10.24411/20715315-2019-12106

25. Martínez G.J., Robertson S., Barraclough J., Xia Q., Mallat Z., Bursill C., Celermajer D.S., Patel S. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. J. Am. Heart Assoc. 2015;4(8):4:e002128. doi: 10.1161/JAHA.115.002128

26. Åkerblom A., James S.K., Lakic T.G., Becker R., Cannon C., Steg P., Himmelmann A., Katus H., Storey R., Wallentin L., Weaver W., SiegbahnA., PLATO Investigators. Interleukin-18 in patients with acute coronary syndromes. Clin. Cardiol. 2019;2(12):1202– 1209. doi: 10.1002/clc.23274

27. Tepljakov A.T., Kuznecova A.V., Protopopova N.V., Andriyanova A.V., Suslova T.E., Nasanova O.N., Kalyuzhin V.V. Lipoprotein-associated phospholipase a2 in cardiovascular risk stratification after coronary stenting in patients with type 2 diabetes mellitus: which decision rule threshold to choose? Byulleten’ sibirskoy meditsiny = Bulletin of Siberian Medicine. 2015;14(2):47–54. [In Russian]. doi: 10.20538/16820363-2015-2-47-54

28. Shherbak S.G., Lisovec D.G., Sarana A.M, Kamilova T.A., Glotov O.S., Anisenkova A.Ju., Apal’ko S.V., Urazov S.P. Biomarkers of cardiovascular disease. Fizicheskaya i reabilitatsionnaya meditsina = Physical and Rehabilitation Medicine. 2019;1(2):60– 76. [In Russian]. doi: 10.36425/2658-6843-19190

29. Held C., White H.D., Stewart R.A.H., Budaj A., Cannon C., Hochman J., Koenig W., Siegbahn A., Steg P.G., Soffer J., … STABILITY Investigators. Inflammatory biomarkers interleukin-6 and C-reactive protein and outcomes in stable coronary heart disease: Experiences from the STABILITY (Stabilization of atherosclerotic plaque by initiation of darapladib therapy) trial. J. Am. Heart. Assoc. 2017;6(10):e005077. doi: 10.1161/JAHA.116.005077

30. Fujita D., Preiss L., Aizawa K. Circulating interleukin-6 (IL-6) levels are associated with aortic dimensions in genetic aortic conditions. PLoS ONE. 2019;14(3):e0214084. doi: 10.1371/journal. pone.0214084

31. Dyleva Ju.A., Gruzdeva O.V., Uchasova E.G., Kuzmina A.A., Karetnikova V.N. Stimulating growth factor ST2 in cardiology: present and prospects. Lechashchiy vrach = Therapist. 2017;11:65–65. [In Russian].

32. Barbarash O.L., Gruzdeva O.V., Pecherina T.B., Akbasheva O.E., Borodkina D.A., Kashtalap V.V., Karetnikova V.N., Kokov A.N., Brel N. K., Dyleva Yu.A., ... Kuzmina A.A. Predictors of the development of cardiofibrosis and cachexia of epicardial adipose tissue in the late period of myocardial infarction. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2020;25(2):3474. [In Russian]. doi: 10.15829/1560-4071-2020-2-3474

33. Carlsson A.C., Ruge T., Kjoller E., Hilden J., Kolmos H., Sajadieh A., Kastrup J., Jensen G., Larsson A., Nowak C., … Ärnlöv J. 10-year associations between tumor necrosis factor receptors 1 and 2 and cardiovascular events in patients with stable coronary heart disease: A CLARICOR (effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease) trial substudy. J. Am. Heart. Assoc. 2018;7(9):e008299. doi: 10.1161/JAHA.117.008299

34. Chen X.L., Li Q., Huang W.S., Lin Y.-S., Xue J., Wang B., Jin K.-L., Shao B. Serum YKL-40, a prognostic marker in patients with large-artery atherosclerotic stroke. Acta Neurol. Scand. 2017;136(2):97–102. doi: 10.1111/ane.12688

35. Gracheva S.A., Klefortova I.I., Shamhalova M.Sh. Prevalence of combined atherosclerotic vascular lesions in patients with diabetes mellitus. Saharnyy diabet = Diabetes. 2012;15(1):49–55. [In Russian]. doi: 10.14341/2072-0351-5979

36. Topchieva L.V., Korneva V.A., Kurbatova I.V. The relationship of the carriership of allelic variations in rs2228145 (A > C) of the IL6R gene with the levels of VCAM1 and ICAM1 gene transcripts in patients with essential hypertension. Vavilovskii Zhurnal Genet Selektsii. 2020;24(1):96–101. doi: 10.18699/VJ20.600

37. Bobko O.V., Tihomirova O.V., Zybina N.N., Frolova M.Yu. Desynchronosis markers in risk assessment of metabolic syndrome development. Meditsinskiy alfavit = Medical Alphabet. 2019;1(4):21–-26. [In Russian]. doi: 10.33667/2078-5631-2019-1-4(379)-2126

38. Zholbaeva A.Z., Tabina A.E., Goluhova E.Z. Molecular mechanisms of atrial fibrillation: in search of the “ideal” marker. Kreativnaya kardiologiya = Creative Cardiology. 2015;2:40–53. [In Russian]. doi: 10.15275/kreatkard.2015.02.04

39. Dunaevskaja S.S., Vinnik Ju.S. The development of endothelial dysfunction in obliterating atherosclerosis of the vessels of the lower extremities and markers for predicting the course of the disease. Byulleten’ sibirskoy meditsiny = Bulletin of Siberian Medicine. 2017;16(1):108–118. [In Russian]. doi: 10.20538/1682-0363-2017-1-108-118

40. Ustjuzhanina M.A., Kovtun O.P., Car’kova S.A. Apolipoproteins B and A1 in pediatric practice as markers of the risk of developing cardiovascular diseases. Ural’skiy meditsinskiy zhurnal = Ural Medical Journal. 2017;5:74–78. [In Russian].

41. Wang W., Blackett P., Khan S., Lee E. Apolipoproteins A-I, B, and C-III and obesity in young adult cherokee. J. Lipids. 2017:8236325. doi: 10.1155/2017/8236325

42. Aleksandrov A.A., Leont’eva I.V., Rozanov V.B., Isaikina O.Yu., Kotova M.B. The effect of burdened heredity for cardiovascular diseases on the levels and outcomes of risk factors in children: results of a 32-year prospective follow-up. Profilakticheskaya meditsina = The Russian Journal of Preventive Medicine and Public Health. 2019;22(3):37–43. [In Russian]. doi: 10.17116/profmed20192203137

43. Vasjuk Ju.A., Sadulaeva I.A., Jushhuk E.N., Trofimenko O.S., Ivanova S.V. Retinol-binding protein as a marker of cardiovascular risk in patients with arterial hypertension and obesity. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2018;4(156):14-18. [In Russian]. doi: 10.15829/15604071-2018-4-14-18

44. Nalini D., Karthick R., Shirin V., Manohar G., Malathi R. Role of the adipocyte hormone leptin in cardiovascular diseases – a study from Chennai based Population. Thromb. J. 2015;13(12):1–7. doi: 10.1186/ s12959-015-0042-4

45. Mahsudova H.F., Sultanova F.H. Risk factors for cardiovascular disease in obese children. Rehealth Journal. 2020;3-2(7):43–47. [In Russian]. doi: 10.24411/2181-0443/2020-10120

46. Albarracín M.L.G., Torres A.Y.F. Adiponectin and leptin adipocytokines in metabolic syndrome: what is its importance? Dubai Diabetes and Endocrinology Journal. 2020;26:93–102. doi: 10.1159/000510521

47. An Z., Yang G., Zheng H., Nie W., Liu G. Biomarkers in patients with myocardial fibrosis. Open Life Sciences. 2017;12(1):337–344. doi: 10.1515/biol-20170039

48. Shhukin Ju.V., Berezin I.I., Medvedeva E.A., Seleznev E.I., Dyachkov V.A., Slatova L.N. On the value of galectin-3 as a marker and mediator of endogenous inflammation and oxidative-nitrosylating stress in patients with chronic heart failure. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2013;2(100):45–49. [In Russian]. doi: 10.15829/15604071-2013-2-45-49

49. Aliyeva A.M., Reznik E.V., Hasanova E.T., Zhbanov I.V., Nikitin I.G. Clinical significance of the determination of blood biomarkers in patients with chronic heart failure. Arkhiv vnutrnney meditsiny = Archive of Internal Medicine. 2018;8(5):333–345. [In Russian]. doi: 10.20514/2226-6704-2018-8-5-333-345

50. Lebedev D.A., Ljasnikova E.A., Vasil’eva A.A., Vasilyeva E.Yu., Babenko A.Yu., Shlyakhto E.V. Molecular biomarker profile of chronic heart failure with intermediate and preserved left ventricular ejection fraction in the setting of type 2 diabetes mellitus. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2020;25(10):70–78. [In Russian]. doi: 10.15829/15604071-2020-3967

51. Shah A.S.V., Anand A., Strachan F.E., Ferry A., Lee K., Chapman A., Sandeman D., Stables C., Adamson P., Andrews J., … High-STEACS Investigators. High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a steppedwedge, cluster-randomised controlled trial. The Lancet. 2018;392(10151):919–928. doi: 10.1016/ S01406736(18)31923-8

52. Adamson P.D., Anderson J.A., Brook R.D., Calverley P., Celli B., Cowans N., Crim C., Dixon I., Martinez F., Newby D., Vestbo J., Yates J., Mills N. Cardiac troponin i and cardiovascular risk in patients with chronic obstructive pulmonary disease. J. Am. Coll. Cardiol. 2018;72(10):1126–1137. doi: 10.1016/j. jacc.2018.06.051

53. Masljanskij A.L., Zvartau N.Je., Kolesova E.P., Bezkishkiy E.N., Shevchuk I.A., Vasilieva E.Yu., Mazurov V.I., Konradi A.O. Assessment of the functional state of the endothelium in patients with rheumatological diseases. Arterial’naya gipertenziya = Arterial Hypertension. 2015;21(2):168–180. [In Russian]. doi: 10.18705/1607-419X-2015-21-2-168-180

54. Dubchenko E.A., Ivanov A.V., Bojko A.N., Spirina N.N., Gusev E.I., Kubatiev A.A. Hyperhomocysteinemia and endothelial dysfunction in patients with cerebral vascular and autoimmune diseases. Zhurnal nevrologii i psikhiatrii imeni Sergeya Sergeevicha Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(11):133-138. [In Russian]. doi: 10.17116/jnevro2019119111133

55. Agranovich N.V., Anopchenko A.S., Pilipovich L.A., Albotova L.V., Macukatova V.S. Dynamics of the profile of biochemical markers of arterial hypertension in elderly patients under the influence of physical activity. Voprosy kurortologii, fizioterapii i lechebnoy fizicheskoy kul’tury = Problems of Balneology, Physiotherapy, and Exercise Therapy. 2019;1:4–10. [In Russian]. doi: 10.17116/kurort2019960114

56. Noutsias M., Hohmann C., Pauschinger M., Schwimmbeck P., Ostermann K., Rode U., Yacoub M.H., Kühl U., Schultheiss H. sICAM-1 correlates with myocardial ICAM-1 expression in dilated cardiomyopathy. Int. J. Cardiol. 2003;91(2-3):153–161. doi: 10.1016/ S0167-5273(03)00033-0